Sharps Technology Inc., (STSS) News
Filter STSS News Items
STSS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest STSS News From Around the Web
Below are the latest news stories about SHARPS TECHNOLOGY INC that investors may wish to consider to help them evaluate STSS as an investment opportunity.
Sharps Technology’s CEO Issues Shareholder Letter Highlighting Hungary Manufacturing Facility Expansion Plans to Increase SecureGard and SoloGard Product Supply and RevenueShareholder letter includes details about the $50+ million sales agreement with a US-based pharma company, plans for Hungary SoloGard manufacturing expansion, and expected delivery scheduleInitial production and commercial deliveries to begin in Q1 2025 Sales team has signed an agreement to sell and deliver current SecureGard 1mL and 3mL inventory, with shipments and revenue that began in early December NEW YORK, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: “STSS” and “STS |
Sharps Technology Signs Sales Agreements to Support Major European Healthcare Network and Sells Out Its Inventory for SecureGardSigned multiple agreements to sell its SecureGard syringe inventory, with initial shipments and revenue commencing in early DecemberAgreements also include new forecasted orders and commitments for all current SecureGard capacity, to begin in Q2 2025The SecureGard agreements will strengthen the potential revenue curve for the Hungary Operation starting in 2024 NEW YORK, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharma |
Sharps Regains Nasdaq Listing ComplianceNEW YORK, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: “STSS” and “STSSW”) (“Sharps”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced that on November 13, 2024, the Company was notified by the Nasdaq Stock Market (“Nasdaq”) that the Company had regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Stock Market, as set forth in Nas |
Sharps Technology, Inc. Announces Stockholders’ Approval of Reverse Stock Split Ratio and Effective DateNEW YORK, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: “STSS” and “STSSW”) ("Sharps"), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced that it will effect a one-for-22 reverse stock split (the "reverse split") of its common stock, par value $0.0001 per share (the "Common Stock"), that will become effective on October 15, 2024 at 11:59 PM Eastern Time, before the opening of trading on The Na |
Empery Asset Management's Strategic Reduction in Sharps Technology IncOn September 30, 2024, Empery Asset Management, LP (Trades, Portfolio) executed a significant transaction involving the sale of 452,869 shares of Sharps Technology Inc (NASDAQ:STSS), a noted player in the medical devices sector. This move adjusted their holding to a total of 783,613 shares, marking a notable shift in their investment strategy regarding this stock. Located at 1 Rockefeller Plaza, New York, Empery Asset Management, LP (Trades, Portfolio) is known for its sharp investment strategies and a keen focus on maximizing returns. |
Sharps Technology, Inc. Reminds Shareholders to Vote Before Important Shareholder Meeting on October 7, 2024NEW YORK, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: STSS) (the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is reminding shareholders to vote their proxy in favor of the Company’s proposal before the shareholder meeting scheduled to be held on October 7, 2024 at 10:00 a.m. Eastern Time. “Please take a very important step to preserve your investment and to help ensure that Sharps Technolo |
Aegis Capital Corp. Acted as Exclusive Placement Agent on a $3.5 Million Bridge Financing for Sharps Technology, Inc. (NASDAQ:STSS)NEW YORK, NY / ACCESSWIRE / September 27, 2024 / Aegis Capital Corp. acted as Exclusive Placement Agent on a $3.5 Million Bridge Financing for Sharps Technology, Inc. (NASDAQ:STSS). About Sharps Technology, Inc. Sharps Technology, Inc., a medical ... |
Sharps Technology, Inc. Closes $3.5 Million Bridge FinancingNEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: STSS) (the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced the closing of its previously announced secured bridge loan financing (the “Bridge Financing”) of approximately $3.5 million. The Bridge Financing consisted of the sale of approximately $3.5 million in securities, with purchasers agreeing to buy, for each $1,000 inv |
Sharps Technology, Inc. Announces $3.5 Million Bridge FinancingNEW YORK, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: STSS) (the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced that it has entered into definitive agreements with institutional investors for a secured bridge loan financing (the “Bridge Financing”) of approximately $3.5 million. The Bridge Financing consisted of the sale of approximately $3.5 million in securities, with purch |
Sharps Technology Announces Continued Listing on Nasdaq Pending Results of an Upcoming Special Shareholders’ MeetingNEW YORK, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: STSS and STSSW) (“Sharps Technology” or the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, announced today that the Company has secured approval from The Nasdaq Stock Market (“Nasdaq” or the “Exchange”) to maintain its listing, subject to conditions outlined below. On September 9, 2024, Sharps Technology received a Determination Letter f |